Clinical Trial: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Subjects With Pyoderma Gangrenosum

Study Status: Terminated
Recruit Status: Terminated
Study Type: Interventional

Official Title: A 2-Year, Open-Label, Safety Extension Study of Gevokizumab in Patients With Pyoderma Gangrenosum

Brief Summary: The study will evaluate the long-term safety of gevokizumab in treating active PG ulcers

Detailed Summary:
Sponsor: XOMA (US) LLC

Current Primary Outcome:

  • Evaluation of treatment-emergent adverse events; [ Time Frame: Up to 2 years ]
  • Changes from baseline vital signs, physical examination results, and laboratory test results [ Time Frame: Up to 2 years ]
  • Changes from baseline concomitant medications use [ Time Frame: Up to 2 years ]


Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: XOMA (US) LLC

Dates:
Date Received: December 8, 2014
Date Started: November 2014
Date Completion:
Last Updated: April 25, 2016
Last Verified: April 2016